Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05026723
Other study ID # 20-3509
Secondary ID R01DK127365
Status Recruiting
Phase N/A
First received
Last updated
Start date October 4, 2021
Est. completion date February 2027

Study information

Verified date November 2023
Source University of North Carolina, Chapel Hill
Contact Katharine Ricks, PhD
Phone 919-843-6637
Email kathier1@email.unc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-site, open-label, Phase II, community-based randomized controlled explanatory trial to test the efficacy of a medically tailored meal + intensive lifestyle intervention (MTM + ILI) intervention for adults with food insecurity, HIV, and T2DM or high risk of T2DM, compared with a group that receives usual MTM.


Description:

In contemporary practice for people with HIV, type 2 diabetes mellitus (T2DM) has become an important comorbidity. T2DM is 1.5 times more common in people with HIV than the general population. Among those with T2DM, people with HIV have greater risk for weight gain, lower diet quality, and higher hemoglobin A1c. All of this puts people with HIV and T2DM at substantial risk for complications, including chronic kidney disease, cardiovascular disease, and premature mortality. Food insecurity, "lack of access to enough food for an active, healthy life", is a major contributor to this risk. Food insecurity is 2 to 3 times more common among people with HIV than the general population. Food insecurity is associated with both worse T2DM control and more T2DM complications. Medically tailored meal home delivery programs relieve food insecurity for people with HIV. Medically tailored meals emerged to treat food insecurity among those with AIDS in the 1990's. Medically tailored meal programs deliver fully prepared meals, tailored by a registered dietitian to an individual's medical needs. Although HIV care has changed, medically tailored meal interventions for people with HIV have not kept pace. Most medically tailored meal programs do not provide the intensive lifestyle intervention needed to counter the health threats seen in modern HIV care. These threats include the metabolic effects of anti-retroviral medications, chronic inflammation, aging, and obesogenic environments. For these reasons, it is critical to test new models of medically tailored meal for people with HIV. The investigators has developed a medically tailored meal intervention that combines meal delivery with an evidence-based lifestyle intervention designed to improve weight loss and diabetes self-management. The goal for this project is to test whether this medically tailored meal intervention can lead to improvements in weight, hemoglobin A1c, and in patient-reported outcomes such as food insecurity, quality of life, and diabetes distress, compared with a standard medically tailored meal intervention. Thus, the investigators propose a randomized comparative effectiveness trial to assess a community-based medically tailored meals intervention (n=200). It will be conducted among diverse participants with HIV and T2DM or high risk for T2DM, referred for medically tailored meals. Adults with hemoglobin A1c less than 12.0%, and BMI ≥ 23 kg/m^2 will be enrolled and randomly assigned to intervention or standard medically tailored meals. The intervention group will receive meal delivery and intensive lifestyle intervention for 12 months, while the comparison group will receive meal delivery along with standard nutrition education for 12 months. Outcomes will be assessed at 6, 12, and 18 months. The primary outcome is weight at 6 months. Secondary outcomes include hemoglobin a1c, food security, quality of life, and diabetes distress.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date February 2027
Est. primary completion date August 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Male or female - Diagnosis of HIV - Diagnosis of Type 2 Diabetes Mellitus or high risk for type 2 diabetes mellitus, defined as meeting CDC eligibility criteria for the diabetes prevention program. Specifically, an individual without a diagnosis of T2DM must 1) have had a blood test result in the prediabetes range within the past year (Hemoglobin A1C: 5.7-6.4% OR Fasting plasma glucose: 100-125 mg/dL OR Two-hour plasma glucose [after a 75 g glucose load]: 140-199 mg/dL), 2) Have been previously diagnosed with gestational diabetes, OR 3) have a high-risk result (score of 5 or higher) on the Prediabetes Risk Test (https://www.cdc.gov/prediabetes/pdf/Prediabetes-Risk-Test-Final.pdf) - Experiencing food insecurity as indicated by 2-item Hunger Vital Sign - English speaking - Aged =18 years - BMI = 23 kg/m2 - No plans to move from the area for at least 1 year - Free living to the extent that participant has control over dietary intake - Willing and able to provide written informed consent and participate in all study activities Exclusion Criteria: - Participant in diabetes, nutrition, or weight research intervention in last 12 months - Current AIDS defining illness - Another family member or household member is a study participant. Only one member of each household may take part in this study. - Considering bariatric surgery in the next year or prior bariatric surgery in the past 2 years - Lack of safe, stable residence and ability to store meals - Lack of telephone - Pregnancy/breastfeeding or intended pregnancy in the next year - History of malignancy, other than non-melanoma skin cancer, unless surgically or medically cured > 5 years ago or in remission. Patients with localized prostate and breast cancer diagnosed during the course of routine screening will not be excluded. - Advanced kidney disease (estimated creatinine clearance < 30 ml/min) - Known drug or alcohol misuse in the past 6 months - Known psychosis or major psychiatric illness that prevents participation with study activities - Intermittent use of medications (e.g., oral or intravenous glucocorticoids) that are likely to affect blood sugar

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
MTM + ILI
Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
Standard MTM
Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina

Sponsors (4)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Community Servings, Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Food Insecurity Score at Month 6 Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. 6 Months
Other Food Insecurity Score at Month 12 Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. 12 Months
Other Food Insecurity Score at Month 18 Food Insecurity Score. Score ranges from 0-10, with higher scores indicating greater food insecurity. 18 Months
Other Systolic Blood Pressure at Month 6 Systolic blood pressure in mm Hg 6 Months
Other Systolic Blood Pressure at Month 12 Systolic blood pressure in mm Hg 12 Months
Other Systolic Blood Pressure at Month 18 Systolic blood pressure in mm Hg 18 Months
Other Diastolic Blood Pressure at Month 6 Diastolic blood pressure in mm Hg 6 Months
Other Diastolic Blood Pressure at Month 12 Diastolic blood pressure in mm Hg 12 Months
Other Diastolic Blood Pressure at Month 18 Diastolic blood pressure in mm Hg 18 Months
Other Diet Quality Score at Month 6 Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. 6 months
Other Diet Quality Score at Month 12 Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. 12 months
Other Diet Quality Score at Month 18 Diet Quality as assessed by Brief Dietary Assessment Scale. This score is comprised of 3 sections (or subscales) used to assess dietary patterns. Subscales are scored independently. The subscales are: Vegetables, Fruit, Whole Grains, and Beans subscale (range 0 - 20), Drinks, Desserts, Snacks, Eating Out, and Salt subscale (range 0- 20), and Fish, Meat, Poultry, Dairy, and Eggs subscale (range 0-10): Total score equals the sum of the 3 subscales. For subscales and total score, higher scores indicates better diet quality. 18 months
Other Cost-Related Medication Underuse at Month 6 Any affirmative response to cost-related medication underuse items 6 months
Other Cost-Related Medication Underuse at Month 12 Any affirmative response to cost-related medication underuse items 12 months
Other Cost-Related Medication Underuse at Month 18 Any affirmative response to cost-related medication underuse items 18 months
Other Adherence to Refills and Medications Scale-Diabetes (ARMS-D) Medication Adherence Score at Month 6 Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. 6 months
Other ARMS-D Medication Adherence Score at Month 12 Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. 12 months
Other ARMS-D Medication Adherence Score at Month 18 Medication Adherence as assessed by 7-item ARMS-D scale. Scores range from 7 to 28, with higher scores indicating more problems with adherence. 18 months
Other Diabetes Self-Care Activities Medication Adherence Score at Month 6 Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. 6 months
Other Diabetes Self-Care Activities Medication Adherence Score at Month 12 Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. 12 months
Other Diabetes Self-Care Activities Medication Adherence Score at Month 18 Medication Adherence as assessed by 1-item summary of diabetes self-care activities measure. Scores range from 0-7 with higher scores indicating better adherence. 18 months
Other Diet Self-Efficacy Score at Month 6 Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. 6 months
Other Diet Self-Efficacy Score at Month 12 Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. 12 months
Other Diet Self-Efficacy Score at Month 18 Diet Self-Efficacy as assessed by cardiac diet self-efficacy scale. Scores range from 16 to 80 with higher scores indicating greater self-efficacy. 18 months
Other Perceived Diabetes Self-Management Self-Efficacy Score at Month 6 Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy 6 months
Other Perceived Diabetes Self-Management Self-Efficacy Score at Month 12 Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy 12 months
Other Perceived Diabetes Self-Management Self-Efficacy Score at Month 18 Diabetes Self-Efficacy as assessed by Perceived Diabetes Self-Management Scale. Scores range from 8 to 40 with higher scores indicating greater self-efficacy 18 months
Other Stress Score at 6 months Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. 6 months
Other Stress Score at 12 months Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. 12 months
Other Stress Score at 18 months Stress as assessed by perceived stress scale. Scores range from 0 to 40 with higher scores indicating higher perceived stress. 18 months
Other Food/Medication Trade-offs at Month 6 Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. 6 months
Other Food/Medication Trade-offs at Month 12 Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. 12 months
Other Food/Medication Trade-offs at Month 18 Single item-indicators of trading off medication for food or food for medication. An affirmative response indicates the presence of a trade-off. 18 months
Other Cluster of Differentiation 4 (CD4+) Count at Month 6 CD4+ Count 6 Months
Other Self-Reported CD4+ Count at Month 6 Self-Reported CD4+ Count 6 Months
Other Self-Reported CD4+ Count at Month 12 Self-Reported CD4+ Count 12 Months
Other Self-Reported CD4+ Count at Month 18 Self-Reported CD4+ Count 18 Months
Other HIV Viral Load at Month 6 HIV Viral Load 6 Months
Other Self-Reported HIV Viral Load at Month 6 Self-Reported HIV Viral Load 6 Months
Other Self-Reported HIV Viral Load at Month 12 Self-Reported HIV Viral Load 12 Months
Other Self-Reported HIV Viral Load at Month 18 Self-Reported HIV Viral Load 18 Months
Other C-Reactive Protein (CRP) at Month 6 C-Reactive Protein 6 months
Primary Bodyweight at Month 6 Bodyweight measured in Kg 6 months
Secondary Bodyweight at Month 12 Bodyweight measured in Kg 12 months
Secondary Bodyweight at Month 18 Bodyweight measured in Kg 18 months
Secondary Hemoglobin A1c at Month 6 Hemoglobin A1c Level 6 months
Secondary Hemoglobin A1c at Month 12 Hemoglobin A1c Level 12 months
Secondary Hemoglobin A1c at Month 18 Hemoglobin A1c Level 18 months
Secondary Health-Related Quality of Life Score as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS)-29 at Month 6 The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). 6 months
Secondary Health-Related Quality of Life Score as assessed by PROMIS-29 at Month 12 The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). 12 months
Secondary Health-Related Quality of Life Score as assessed by PROMIS-29 at Month 18 The PROMIS-29 includes seven health related quality of life domains (Physical Functioning, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Functioning, and Pain), and the pain domain has two subdomains (interference and intensity). Raw scores, except pain intensity, are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on physical function indicates better functioning, whereas a higher score on depression indicates more severe depressive symptoms. Will report overall score and scores for each domain. From these data will also calculate a PROMIS-Preference (PROPr score) (PROPr scores range from -0.022 (worst) to 1.0 (best)). 18 months
Secondary Depressive Symptom Score at Month 6 Depressive Symptoms as assessed by PROMIS Short Form (PROMIS SF) v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. 6 months
Secondary Depressive Symptom Score at Month 12 Depressive Symptoms as assessed by PROMIS SF v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. 12 months
Secondary Depressive Symptom Score at Month 18 Depressive Symptoms as assessed by PROMIS SF v1.0 - Depression 4a. Raw scores are transformed using the T-score metric based on the item response theory calibrations in which scores have a mean of 50 and standard deviation of 10 for the general population in the US. A higher PROMIS T-score implies more of the concept being measured; i.e., a higher PROMIS score on depression indicates more severe depressive symptoms. 18 months
Secondary Diabetes Distress Score as assessed by Problem Areas in Diabetes (PAID)-11 at Month 6 Score ranges from 11-55 with higher scores indicating greater diabetes distress 6 months
Secondary Diabetes Distress Score as assessed by PAID-11 at Month 12 Score ranges from 11-55 with higher scores indicating greater diabetes distress 12 months
Secondary Diabetes Distress Score as assessed by PAID-11 at Month 18 Score ranges from 11-55 with higher scores indicating greater diabetes distress 18 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2